References
- Ameratunga R, Woon ST, Jordan A, et al. Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection. Expert Rev Clin Immunol. 2021;17(5):421–430. Epub 1742021 Apr 1744626.
- Ameratunga R, Longhurst H, Steele R, et al. Common variable immunodeficiency disorders, T cell responses to SARS-CoV-2 vaccines and the risk of chronic COVID-19. J Allergy Clin Immunol In Prac. LID - S2213-2198(21) 00702-9[pii] LID. 2021. (2213-2201 (Electronic)). DOI:https://doi.org/10.1016/j.jaip.2021.06.019
- Editorial. Facing up to long COVID. Lancet. 2020;396(10266):1861.
- Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848.
- Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. N Engl J Med. LID - S1198-743X(21)00367-0 [pii] LID. (1469-0691 (Electronic))). DOI:https://doi.org/10.1016/j.cmi.2021.06.036
- Ameratunga R, Allan C, Woon ST. Defining common variable immunodeficiency disorders in 2020. Immunol Allergy Clin North Am. 2020;40(3):403–420.
- Ameratunga R, Longhurst HJ, Steele R, et al. Comparison of diagnostic criteria for common variable immunodeficiency disorders (CVID) in the New Zealand CVID study. Clin Rev Allergy Immunol. 2021;61:236–244.
- Ameratunga R, Ahn Y, Steele R, et al. The natural history of untreated primary hypogammaglobulinemia in adults: implications for the diagnosis and treatment of common variable immunodeficiency disorders (CVID). Front Immunol. 2019;10:1541.
- Hensley MK, Bain WG, Jacobs J, et al. Intractable COVID-19 and prolonged SARS-CoV-2 replication in a CAR-T-cell therapy recipient: a case study. Clin Infect Dis. 2021 Aug 2;73(3):e815-e821. DOI:https://doi.org/10.1093/cid/ciab072.
- Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291–2293.
- Ameratunga R, Lederman HM, Sullivan KE, et al. Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1 Pt 1):147–150.
- Ameratunga R, Woon ST, Koopmans W, et al. Cellular and molecular characterisation of the hyper immunoglobulin M syndrome associated with congenital rubella infection. J Clin Immunol. 2009;29(1):99–106.
- Ameratunga R, Lehnert K, Leung E, et al. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. N Z Med J. 2020;133(1515):112–118.
- Ameratunga R, Woon ST, Steele R, et al. Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. LID. Expert Rev Clin Immunol. 2021;17:553–560. (1744-8409 (Electronic)).